These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 14661043)

  • 1. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.
    Vasey PA
    Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S23-8. PubMed ID: 14661043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
    Monk BJ; Coleman RL
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Du XL; Parikh RC; Lairson DR; Giordano SH; Cen P
    Med Oncol; 2013 Mar; 30(1):440. PubMed ID: 23307252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical management of ovarian cancer : current status.
    Markman M
    Drugs; 2008; 68(6):771-89. PubMed ID: 18416585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
    Newman G
    Lancet; 2003 Oct; 362(9392):1333; author reply 1334. PubMed ID: 14575996
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.
    Palmieri C; Gojis O; Rudraraju B; Stamp-Vincent C; Wilson D; Langdon S; Gourley C; Faratian D
    Br J Cancer; 2013 May; 108(10):2039-44. PubMed ID: 23652306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):19-24. PubMed ID: 15726535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
    Kelly MG; Mor G; Husband A; O'Malley DM; Baker L; Azodi M; Schwartz PE; Rutherford TJ
    Int J Gynecol Cancer; 2011 May; 21(4):633-9. PubMed ID: 21412168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.
    Stuart GC
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S8-15. PubMed ID: 13129490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
    Matsuo K; Eno ML; Im DD; Rosenshein NB
    Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental chemotherapy and management of recurrent ovarian cancer.
    Bookman MA
    J Clin Oncol; 2003 May; 21(10 Suppl):149s-167s. PubMed ID: 17633784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
    Seamon LG; Carlson MJ; Richardson DL; Cohn DE; Fowler JM; Copeland LJ; O'Malley DM
    Int J Gynecol Cancer; 2009 Oct; 19(7):1195-8. PubMed ID: 19823054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.
    Stordal B; Pavlakis N; Davey R
    Cancer Treat Rev; 2007 Dec; 33(8):688-703. PubMed ID: 17881133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
    Kodaz H; Hacibekiroglu I; Turkmen E; Erdogan B; Elpen C; Uzunoglu S; Cicin I
    Tumori; 2015; 101(1):36-40. PubMed ID: 25702671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational use of cytotoxic chemotherapy for recurrent ovarian cancer.
    Liu J; Matulonis U
    J Natl Compr Canc Netw; 2006 Oct; 4(9):947-53. PubMed ID: 17020671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.